3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
14
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
9
Pancreatic Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Colorectal Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Biliary Tract Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Lymphoma, Follicular
3
Kidney Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Uterine Cervical Neoplasms
2
Recurrence
2
Oropharyngeal Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Interventions
Cyclophosphamide
18
fludarabine phosphate
16
Rituximab
16
Etoposide
16
Peripheral Blood Stem Cell Transplantation
14
Brentuximab Vedotin
14
fludarabine
11
Whole-Body Irradiation
11
Nivolumab
11
Mycophenolic Acid
11
Bendamustine Hydrochloride
11
Tacrolimus
10
Melphalan
10
Filgrastim
9
Gemcitabine
8
Carboplatin
8
Ifosfamide
7
Cytarabine
7
Cyclosporine
7
Busulfan
7
pembrolizumab
6
Lenalidomide
6
Doxorubicin
6
Prednisone
5
Everolimus
5
Antilymphocyte Serum
5
Alemtuzumab
5
Vinblastine
4
Methotrexate
4
Mesna
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Hodgkin Disease
×
durvalumab
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts